<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933682</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN2050-HV-105</org_study_id>
    <nct_id>NCT04933682</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1 Two-Part Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Fluconazole, and Between ALXN2050 and Rifampin in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction&#xD;
      between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in&#xD;
      healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a&#xD;
      single-period, fixed-sequence study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a 2-part, open-label, fixed-sequence study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under The Concentration-time Curve From Time 0 To Infinity (AUC0-inf) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Concentration (Cmax) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time To Maximum Plasma Concentration (Tmax) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under The Concentration-time Curve From Time 0 To The 12-hour Point (AUC0-12) For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cmax For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Tmax For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under The Concentration-time Curve From Time Zero To The 4-hour Time Point (AUC0-4) For ALXN2050 When Dosed In The Morning Versus In The Evening</measure>
    <time_frame>Up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>Up to 40 days postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: ALXN2050 plus Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive a single dose of ALXN2050 alone and in the presence of multiple doses of fluconazole.&#xD;
Period 2: Participants will receive multiple doses of ALXN2050 alone and in the presence of multiple doses of fluconazole.&#xD;
Scheduled pharmacokinetics (PK) blood samples for both ALXN2050 and fluconazole will be collected, with a washout period of at least 14 days between the last dose of fluconazole in Period 1 and the first dose of ALXN2050 in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: ALXN2050 plus Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN2050 alone and in the presence of both single and multiple doses of rifampin.&#xD;
Scheduled PK blood samples for both ALXN2050 and rifampin will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 1: ALXN2050 plus Fluconazole</arm_group_label>
    <arm_group_label>Part 2: ALXN2050 plus Rifampin</arm_group_label>
    <other_name>ACH-0145228 (formerly)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 1: ALXN2050 plus Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Oral capsule.</description>
    <arm_group_label>Part 2: ALXN2050 plus Rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Medically healthy with no clinically significant or relevant abnormalities as&#xD;
             determined by medical history, physical or neurological examination, vital signs,&#xD;
             12-lead electrocardiogram, screening clinical laboratory profiles.&#xD;
&#xD;
          -  Body mass index within the range 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at Screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies.&#xD;
&#xD;
          -  Any previous procedure that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          -  Participation in another investigational drug or investigational device study within 5&#xD;
             half-lives (if known) or 30 days prior to the first dose of study intervention,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  Body temperature ≥ 38.0°Celsius, at Screening or prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  History of drug or alcohol abuse within 2 years prior to the first dose of study&#xD;
             intervention or positive drugs-of-abuse or alcohol screen at Screening or Day -1;&#xD;
             current tobacco/nicotine user or smoker or a positive cotinine test at Screening.&#xD;
&#xD;
          -  Donation of whole blood from 3 months prior to the first dose of study intervention,&#xD;
             or of plasma from 30 days prior to the first dose of study intervention; receipt of&#xD;
             blood products within 6 months prior to the first dose of study intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>1-855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALXN2050</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Rifampin</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

